SCHEMBL3671016

SCHEMBL3671016

CC(NC1CCCCC1)c1ccccc1

nearest known ligand 0.96

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.96
L3MBTL1 Q9Y468 1/20 0.96
EPHX1 P07099 2/20 0.59
LMNA P02545 1/20 0.59
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
POLB P06746 1/20 0.49
ATM Q13315 1/20 0.49
CYP3A4 P08684 1/20 0.47
HPGD P15428 1/20 0.47
CYP2C19 P33261 1/20 0.47
RAB9A P51151 1/20 0.47
RECQL P46063 2/20 0.47
NPSR1 Q6W5P4 3/20 0.47
HTT P42858 2/20 0.47
CNR1 P21554 2/20 0.47
CNR2 P34972 2/20 0.47
ALDH1A1 P00352 1/20 0.46
IDO1 P14902 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3665297 1.00 GAA (0.96) GAAL3MBTL1EPHX1LMNAMEN1
SCHEMBL28091017 1.00 GAA (0.96) GAAL3MBTL1EPHX1LMNAMEN1
SCHEMBL21104687 1.00 GAA (0.96) GAAL3MBTL1EPHX1LMNAMEN1
Hydrochloric Acid SCHEMBL28720089 0.98 GAA (0.93) GAAL3MBTL1EPHX1LMNAMEN1
SCHEMBL3668041 0.98 GAA (1.00) GAAL3MBTL1EPHX1LMNAMEN1
SCHEMBL664938 0.90 GAA (0.85) GAAL3MBTL1EPHX1LMNAMEN1
SCHEMBL27818229 0.90 GAA (0.85) GAAL3MBTL1EPHX1LMNAMEN1
SCHEMBL7751819 0.83 GAA (0.73) GAAL3MBTL1EPHX1LMNAMEN1
SCHEMBL3665477 0.81 GAA (0.71) GAAL3MBTL1EPHX1LMNAMEN1
SCHEMBL4153139 0.81 GAA (0.71) GAAL3MBTL1EPHX1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101970394-A Novel cyclic hydrocarbon compounds for the treatment of diseases LEO PHARMA AS 2011-02-09 CN claimed
US-20100317582-A1 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-12-16 US claimed
EP-2234961-A2 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-10-06 EP claimed
WO-2009065406-A2 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2009-05-28 WO claimed
CN-117343047-A Bimetal synergistic promotion system and application thereof in asymmetric synthesis of (R, S) -TBAJ-876 上海交通大学 2024-01-05 CN disclosed
EP-4245756-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF Gilead Sciences, Inc. (US) 2023-09-20 EP disclosed
US-20210340331-A1 POLYAMINOBORANES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) 2021-11-04 US disclosed
US-11091593-B2 Polyaminoboranes CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2021-08-17 US disclosed
WO-2018138384-A1 POLYAMINOBORANES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-08-02 WO disclosed
CN-105873927-B 4-azaindole derivatives 卫材R&D管理有限公司 2017-11-28 CN disclosed
WO-2017029602-A2 COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-02-23 WO disclosed
US-9487494-B2 Cyclic hydrocarbon compounds for the treatment of diseases LEO PHARMA A/S (DK) 2016-11-08 US disclosed
CN-101970394-B Novel cyclic hydrocarbon compounds for the treatment of diseases LEO PHARMA AS 2015-05-27 CN disclosed
US-20150073165-A1 CATALYST COMPOUNDS THE UNIVIERSITY OF LIVERPOOL (GB) 2015-03-12 US disclosed
US-20150073165-A1 CATALYST COMPOUNDS THE UNIVIERSITY OF LIVERPOOL (GB) 2015-03-12 US disclosed
WO-2013153408-A1 CATALYST COMPOUNDS THE UNIVERSITY OF LIVERPOOL (GB) 2013-10-17 WO disclosed
CN-101970394-A Novel cyclic hydrocarbon compounds for the treatment of diseases LEO PHARMA AS 2011-02-09 CN disclosed
US-20100317582-A1 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-12-16 US disclosed
EP-2234961-A2 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-10-06 EP disclosed
WO-2009065406-A2 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317582-A1 NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES ARNT, AHR, CYP27A1 GAA 1308/4885L3MBTL1 4065/4885EPHX1 320/4885
US-20150073165-A1 CATALYST COMPOUNDS NQO1, IDH2, IDH3B GAA 3286/4885L3MBTL1 4548/4885EPHX1 2911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.